Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT05415215
What this trial is testing

Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Who this might be right for
Early Breast CancerLocally Advanced Breast CancerInflammatory Breast Cancer
Hoffmann-La Roche 346
Testing effectiveness (Phase 2)Study completedNCT00148668
What this trial is testing

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Eric Winer, MD 81
Large-scale testing (Phase 3)Looking for participantsNCT07400523
What this trial is testing

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 446
Post-approval studies (Phase 4)UnknownNCT05809024
What this trial is testing

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Who this might be right for
Locally Advanced Breast CancerHormone Receptor Positive，HER2-negative Breast Cancer
Yongsheng Wang 100
Large-scale testing (Phase 3)Study completedNCT01901146
What this trial is testing

Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
Amgen 725
Testing effectiveness (Phase 2)Study completedNCT00976989
What this trial is testing

Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 225
Post-approval studies (Phase 4)UnknownNCT05302336
What this trial is testing

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast CancerChemotherapeutic Toxicity
Second Affiliated Hospital, Zhejiang University, School of Medicine 402
Testing effectiveness (Phase 2)UnknownNCT04152057
What this trial is testing

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Who this might be right for
Breast CancerHER2 PositiveCombination Chemotherapy
West China Hospital 20
Not applicableNot Yet RecruitingNCT07706933
What this trial is testing

Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 456
Large-scale testing (Phase 3)Study completedNCT01964391
What this trial is testing

Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 174
Early research (Phase 1)Enrolling By InvitationNCT06671691
What this trial is testing

A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)SBRT
Universitat de les Illes Balears 15
Post-approval studies (Phase 4)Looking for participantsNCT05333328
What this trial is testing

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorHER2-negative Breast Cancer+2 more
Gangnam Severance Hospital 418
Testing effectiveness (Phase 2)Study completedNCT03272477
What this trial is testing

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Who this might be right for
Breast Neoplasms
Palleos Healthcare GmbH 257
Not applicableLooking for participantsNCT06650423
What this trial is testing

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Who this might be right for
Early Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer
Institute of Oncology Ljubljana 319
Testing effectiveness (Phase 2)Active Not RecruitingNCT02712723
What this trial is testing

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Qamar Khan 121
Large-scale testing (Phase 3)Ended earlyNCT00543127
What this trial is testing

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 870
Large-scale testing (Phase 3)Study completedNCT03433313
What this trial is testing

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

Who this might be right for
Breast Cancer
EirGenix, Inc. 807
Not applicableStudy completedNCT01834950
What this trial is testing

Identification of Early Markers of Response and Resistance to Trastuzumab

Who this might be right for
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 25
Testing effectiveness (Phase 2)Study completedNCT05896566
What this trial is testing

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 231
Testing effectiveness (Phase 2)Ended earlyNCT03894007
What this trial is testing

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Who this might be right for
Early-stage Breast CancerHER2-positive Breast Cancer
Renske Altena 6
Next Page